Aav9-mediated RNA interference targeting CSTF64 for heart failure therapy
This innovative therapy utilizes AAV9-mediated RNA interference to inhibit CSTF64, aiming to reduce cardiac fibrosis and improve heart function. Preliminary studies suggest CSTF64 upregulation exacerbates fibrosis, while its inhibition may preserve cardiac function in heart failure models.
Overview
The proposed solution leverages AAV9-mediated siRNA delivery to target and inhibit CSTF64, a protein implicated in exacerbating cardiac fibrosis. By targeting CSTF64, the therapy aims to lengthen the 3'UTR of extracellular matrix (ECM) genes, thereby reducing fibrotic factor production and improving cardiac function. This approach could offer a novel therapeutic pathway for treating heart failure by mitigating fibrosis and preserving cardiac function.
Technical specifications
Key Features:
- Utilizes AAV9 vectors for efficient delivery of CSTF64 siRNA to cardiac tissues.
- Designed to reduce ECM gene expression by altering the 3'UTR length, thereby decreasing fibrotic factors.
- Demonstrated efficacy in mouse models, with planned validation through echocardiography and histological analysis.
- Includes molecular analysis of CSTF64, SMA, and other fibrosis markers to assess therapeutic impact.
Technology readiness level
This therapy is currently at Technology Readiness Level 4, indicating that it has been validated in a laboratory setting using mouse models of heart failure. Further development and validation steps are planned to advance its readiness for clinical application.
About Houston Methodist
Houston Methodist is a large, multi-hospital academic medical center and integrated health system that combines hospital care, research, and education in a clinically embedded environment. Its Academic Institute places laboratory and translational research alongside a major hospital campus in Houston’s Texas Medical Center, enabling access to clinicians, patients, clinical studies, and specialized core facilities. Industry partners can engage through clinical research, sponsored collaborations, hands-on simulation and device evaluation, and preclinical testing in regulated laboratory environments. Research is supported by substantial extramural funding, including major support from the National Institutes of Health and other competitive federal sources. A dedicated Office of Technology Transfer supports invention assessment, licensing, commercialization, and corporate partnerships.
delivered to your inbox.